+353-1-416-8900REST OF WORLD
1-800-526-8630U.S. (TOLL FREE)

Pruritus - Pipeline Review, H1 2017

  • ID: 4115131
  • Report
  • March 2017
  • 117 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Albireo Pharma Inc
  • Amorepacific Corp
  • ELORAC Inc
  • J Uriach Y Compania SA
  • Phosphagenics Ltd
  • Teikoku Pharma USA Inc
  • MORE
Pruritus - Pipeline Review, H1 2017

Summary:

The latest Pharmaceutical and Healthcare disease pipeline guide Pruritus - Pipeline Review, H1 2017, provides an overview of the Pruritus (Dermatology) pipeline landscape.

Pruritus, or itch, is defined as an unpleasant sensation that provokes the desire to scratch. Pruritus is caused by cancer, cancer treatments, infection, dry skin and reaction to a drug. Symptoms include redness, bumps, spots or blisters, dry, cracked skin and leathery or scaly texture to the skin. Risk factors include heat, allergic, asthma, hay fever, hives and eczema. Treatment includes corticosteroids, antihistamines and antidepressants.

Report Highlights:

The latest Pharmaceutical and Healthcare latest pipeline guide Pruritus - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Pruritus (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Pruritus (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Pruritus and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 4, 12, 4, 9 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively.

Pruritus (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Pruritus (Dermatology).
  • The pipeline guide reviews pipeline therapeutics for Pruritus (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Pruritus (Dermatology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Pruritus (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Pruritus (Dermatology)
Reasons to Buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Pruritus (Dermatology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Pruritus (Dermatology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

Loading
LOADING...

3 of 5

FEATURED COMPANIES

  • Albireo Pharma Inc
  • Amorepacific Corp
  • ELORAC Inc
  • J Uriach Y Compania SA
  • Phosphagenics Ltd
  • Teikoku Pharma USA Inc
  • MORE
Introduction

Pruritus - Overview

Pruritus - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Pruritus - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Pruritus - Companies Involved in Therapeutics Development

Albireo Pharma Inc

Allergan Plc

Alveonix AG

Amorepacific Corp

Asana BioSciences LLC

Cara Therapeutics Inc

Chugai Pharmaceutical Co Ltd

ELORAC Inc

GlaxoSmithKline Plc

Hydra Biosciences Inc

J Uriach Y Compania SA

NeuroCycle Therapeutics GmbH

Nippon Shinyaku Co Ltd

Patagonia Pharmaceuticals LLC

Patara Pharma Inc

Phosphagenics Ltd

RDD Pharma Ltd

Sanwa Kagaku Kenkyusho Co Ltd

Shionogi & Co Ltd

Sumitomo Dainippon Pharma Co Ltd

Teikoku Pharma USA Inc

Tioga Pharmaceuticals Inc

Toray Industries Inc

Trevi Therapeutics Inc

Vanda Pharmaceuticals Inc

Pruritus - Drug Profiles

A-4250 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

asimadoline - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ASN-008 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Ax-10 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Ax-8 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cromolyn sodium - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

difelikefalin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GSK-2330672 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lidocaine hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

nalbuphine hydrochloride ER - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

nalfurafine hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

naloxone hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NCT-10001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NCT-10002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NCT-10004 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

nemolizumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NS-141 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

onabotulinumtoxinA - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PAC-14028 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PATN-02 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Peptides to Target TRPV1 for Pain and Itch - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PR-38 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RDD-1609 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rupatadine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

serlopitant - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SK-1405 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule for Pruritus - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Agonize KOR1 for Pruritus - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Agonize CB2 for Pruritus - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize Mas-Related G-Protein Coupled Receptor for Pruritus - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize TRPV3 for Pruritus, Psoriasis and Pain - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SNA-120 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SNA-125 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TPU-010 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tradipitant - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Pruritus - Dormant Projects

Pruritus - Discontinued Products

Pruritus - Product Development Milestones

Featured News & Press Releases

Jan 06, 2017: Menlo Therapeutics Starts Enrollment in Two Phase 2 Studies for Pruritus Associated with Atopic Dermatitis and Pruritus Following Burn Injury

Jan 05, 2017: Menlo Therapeutics Recruits Experienced Management Team and Board Leadership to Accelerate Development of Serlopitant for Treatment of Pruritus

Jun 09, 2016: Cara Therapeutics to Present Preclinical Data at June Medical Meetings

Feb 18, 2016: Cara Therapeutics to Sponsor Symposium and Present Poster at the American Academy of Pain Medicine 32nd Annual Meeting

Oct 26, 2015: Cara Therapeutics to Present at 2nd Human Abuse Liability & Abuse-Deterrent Formulations Conference

Sep 09, 2015: Cara Therapeutics Initiates Phase 3 Program for I.V. CR845 in Acute Postoperative Pain

Jun 11, 2015: Tioga Pharmaceuticals Announces Initiation of Phase 2 Clinical Study of Asimadoline in Patients with Pruritus Associated with Atopic Dermatitis

May 12, 2015: Cara Therapeutics provides update on its Phase 3 Program for I.V. CR845

Apr 15, 2015: Cara Therapeutics to Present at 3rd Conference on the Therapeutic Potential of Kappa Opioids

Mar 19, 2015: Creabilis’ CT327 Phase 2b Data Published in Acta Dermato-Venereologica, Strengthens Scientific Advisory Board

Mar 04, 2015: Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis

Mar 03, 2015: Toray Applies for Japanese Approval of Additional Indication of Pruritus Treatment REMITCH CAPSULES 2.5 µg and Notice Regarding Promotion Tie-up

Jan 12, 2015: Creabilis Receives Positive Feedback on CT327 from US FDA, Providing Clear Path to Registration

Dec 17, 2014: Cara Therapeutics Reports Positive Top-Line Data From Phase 1b Trial of I.V. CR845 in Dialysis Patients

Dec 17, 2014: Velocity Pharmaceutical Development and Tigercat Pharma Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables:

Number of Products under Development for Pruritus, H1

Number of Products under Development by Companies, H1

Number of Products under Development by Companies, H1 2017 (Contd..1), H1

Number of Products under Development by Universities/Institutes, H1

Products under Development by Companies, H1

Products under Development by Companies, H1 2017 (Contd..1), H1

Products under Development by Universities/Institutes, H1

Number of Products by Stage and Target, H1

Number of Products by Stage and Target, H1 2017 (Contd..1), H1

Number of Products by Stage and Mechanism of Action, H1

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1

Number of Products by Stage and Route of Administration, H1

Number of Products by Stage and Molecule Type, H1

Pruritus - Pipeline by Albireo Pharma Inc, H1

Pruritus - Pipeline by Allergan Plc, H1

Pruritus - Pipeline by Alveonix AG, H1

Pruritus - Pipeline by Amorepacific Corp, H1

Pruritus - Pipeline by Asana BioSciences LLC, H1

Pruritus - Pipeline by Cara Therapeutics Inc, H1

Pruritus - Pipeline by Chugai Pharmaceutical Co Ltd, H1

Pruritus - Pipeline by ELORAC Inc, H1

Pruritus - Pipeline by GlaxoSmithKline Plc, H1

Pruritus - Pipeline by Hydra Biosciences Inc, H1

Pruritus - Pipeline by J Uriach Y Compania SA, H1

Pruritus - Pipeline by NeuroCycle Therapeutics GmbH, H1

Pruritus - Pipeline by Nippon Shinyaku Co Ltd, H1

Pruritus - Pipeline by Patagonia Pharmaceuticals LLC, H1

Pruritus - Pipeline by Patara Pharma Inc, H1

Pruritus - Pipeline by Phosphagenics Ltd, H1

Pruritus - Pipeline by RDD Pharma Ltd, H1

Pruritus - Pipeline by Sanwa Kagaku Kenkyusho Co Ltd, H1

Pruritus - Pipeline by Shionogi & Co Ltd, H1

Pruritus - Pipeline by Sumitomo Dainippon Pharma Co Ltd, H1

Pruritus - Pipeline by Teikoku Pharma USA Inc, H1

Pruritus - Pipeline by Tioga Pharmaceuticals Inc, H1

Pruritus - Pipeline by Toray Industries Inc, H1

Pruritus - Pipeline by Trevi Therapeutics Inc, H1

Pruritus - Pipeline by Vanda Pharmaceuticals Inc, H1

Pruritus - Dormant Projects, H1

Pruritus - Discontinued Products, H1

List of Figures:

Number of Products under Development for Pruritus, H1

Number of Products under Development by Companies, H1

Number of Products under Development by Universities/Institutes, H1

Number of Products by Top 10 Targets, H1

Number of Products by Stage and Top 10 Targets, H1

Number of Products by Top 10 Mechanism of Actions, H1

Number of Products by Stage and Top 10 Mechanism of Actions, H1

Number of Products by Routes of Administration, H1

Number of Products by Stage and Routes of Administration, H1

Number of Products by Molecule Types, H1

Number of Products by Stage and Molecule Types, H
Note: Product cover images may vary from those shown
4 of 5
  • Albireo Pharma Inc
  • Allergan Plc
  • Alveonix AG
  • Amorepacific Corp
  • Asana BioSciences LLC
  • Cara Therapeutics Inc
  • Chugai Pharmaceutical Co Ltd
  • ELORAC Inc
  • GlaxoSmithKline Plc
  • Hydra Biosciences Inc
  • J Uriach Y Compania SA
  • NeuroCycle Therapeutics GmbH
  • Nippon Shinyaku Co Ltd
  • Patagonia Pharmaceuticals LLC
  • Patara Pharma Inc
  • Phosphagenics Ltd
  • RDD Pharma Ltd
  • Sanwa Kagaku Kenkyusho Co Ltd
  • Shionogi & Co Ltd
  • Sumitomo Dainippon Pharma Co Ltd
  • Teikoku Pharma USA Inc
  • Tioga Pharmaceuticals Inc
  • Toray Industries Inc
  • Trevi Therapeutics Inc
  • Vanda Pharmaceuticals Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll